|
SAN
DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Nanogen,
Inc. (Nasdaq: NGEN), developer of advanced diagnostic
products, introduced today its second-generation instrument,
the NanoChip(R) 400, at the American Society of Human
Genetics (ASHG) Annual Meeting being held this week
in Toronto. The NanoChip(R) 400 is an advanced molecular
diagnostic testing and diagnostic development platform
for clinical research and clinical reference laboratories.
The automated multi-purpose system facilitates detection
of known genetic sequences, such as single nucleotide
polymorphisms (SNPs), utilizing a 400-site electronic
microarray upon which molecular tests can be developed
and conducted. Building on the features clinical laboratories
and researchers enjoyed with the first-generation
NanoChip(R) Molecular Biology Workstation, the NanoChip(R)
400 offers increased throughput for running multiplex
molecular assays on an instrument that is half the
size of its predecessor. The automated system simplifies
laboratory workflow by minimizing hands-on time.
Well-suited to clinical research
or reference laboratories, the NanoChip(R) 400's ability
to develop and test a user defined panel of mutations
on one chip makes it easier and more cost effective
to use than research-grade thousand-gene chip arrays.
The system is ideal for mid- to high-volume laboratories
where the need to streamline testing and workflow
is a high priority.
Based on patented Nanogen technology
that combines microelectronics and biology, electrical
potential is controlled at each of the 400 test sites
to move and concentrate DNA or RNA, providing accuracy,
speed and flexibility for developing molecular diagnostic
tests. Nanogen's previous 100-site microarray was
the first chip with multiplexing capabilities to be
used by clinical labs in North America, and now customers
can benefit from the NanoChip(R) 400's higher-throughput
and new on-chip memory, which stores critical information
when performing genetic analysis or detecting infectious
disease agents. The NanoChip(R) 400's open-architecture
design permits users to define, select and build their
own test panels or select from Nanogen's predefined
analyte specific reagents (ASRs). ASHG conference
attendees can view demonstrations of the instrument
and learn about Nanogen's same-day technical support
and training available either on-site or at the company's
Customer Applications Laboratory in San Diego.
"The NanoChip(R) 400 incorporates
features requested by customers from their experience
with our first workstation together with Nanogen's
most advanced technology to produce a versatile, reliable
and automated platform for developing and performing
molecular tests in clinical labs," said Howard
C. Birndorf, Nanogen chairman and chief executive
officer. "Our next step in offering advanced
diagnostics will be to build our portfolio of ASRs
to detect genetic mutations and infectious disease
agents. The NanoChip(R) 400 and our growing portfolio
of ASRs will provide our customers a wide variety
of high-quality products for conducting simple to
complex molecular analyses."
The NanoChip(R) 400 is manufactured
by Nanogen's long-standing collaborator Hitachi Instruments
Group under the Food and Drug Administration's Good
Manufacturing Practices guidelines. The instrument
will be available for customers beginning in 2005.
Additional information is available by calling 877-NANOGEN
or by visiting www.nanogen.com.
About Nanogen, Inc.
Nanogen's advanced diagnostics
provide physicians and patients worldwide with sophisticated
information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly
accurate and reliable NanoChip(R) 400, NanoChip(R)
Molecular Biology Workstation, NanoChip(R) Electronic
Microarrays and analyte specific reagents to develop
tests to detect mutations associated with genetic
diseases. Nanogen's subsidiary SynX offers a line
of point-of-care diagnostic tests and is building
expertise in cardiac related health conditions. Nanogen's
ten years of pioneering research involving nanotechnology
may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
|